Abstract
The incidence of cancer and its related morbidity and mortality remain on the increase in both developing and developed countries. Cancer remains a huge burden on the health and social welfare sectors worldwide and its prevention and cure remain two golden goals that science strives to achieve. Among the treatment options for cancer that have emerged in the past 100 years, cancer vaccine immunotherapy seems to present a promising and relatively safer approach as compared to chemotherapy and radiotherapy. The identification of different tumour antigens in the last fifteen years using a variety of techniques, together with the molecular cloning of cytotoxic T lymphocytes (CTLs)- and tumour infiltrating lymphocytes (TILs)-defined tumour antigens allowed more refining of the cancer vaccines that are currently used in different clinical trials. In a proportion of treated patients, some of these vaccines have resulted in partial or complete tumour regression, while they have increased the disease-free survival rate in others. These outcomes are more evident now in patients suffering from melanoma. This review provides an update on melanoma vaccine immunotherapy. Different cancer antigens are reviewed with a detailed description of the melanoma antigens discovered so far. The review also summarises clinical trials and individual clinical cases in which some of the old and current methods to vaccinate against or treat melanoma were used. These include vaccines made of autologous or allogenic melanoma tumour cells, melanoma peptides, recombinant bacterial or viral vectors, or dendritic cells.
Keywords: immunotherapy, malignant melanoma, tumour antigens, human cancer antigen, tyrosinase, melanoma vaccines
Current Pharmaceutical Design
Title: Melanoma Immunotherapy: Past, Present, and Future
Volume: 11 Issue: 27
Author(s): F. Saleh, W. Renno, I. Klepacek, G. Ibrahim, S. Asfar, H. Dashti, P. Romero, A. Dashti and A. Behbehani
Affiliation:
Keywords: immunotherapy, malignant melanoma, tumour antigens, human cancer antigen, tyrosinase, melanoma vaccines
Abstract: The incidence of cancer and its related morbidity and mortality remain on the increase in both developing and developed countries. Cancer remains a huge burden on the health and social welfare sectors worldwide and its prevention and cure remain two golden goals that science strives to achieve. Among the treatment options for cancer that have emerged in the past 100 years, cancer vaccine immunotherapy seems to present a promising and relatively safer approach as compared to chemotherapy and radiotherapy. The identification of different tumour antigens in the last fifteen years using a variety of techniques, together with the molecular cloning of cytotoxic T lymphocytes (CTLs)- and tumour infiltrating lymphocytes (TILs)-defined tumour antigens allowed more refining of the cancer vaccines that are currently used in different clinical trials. In a proportion of treated patients, some of these vaccines have resulted in partial or complete tumour regression, while they have increased the disease-free survival rate in others. These outcomes are more evident now in patients suffering from melanoma. This review provides an update on melanoma vaccine immunotherapy. Different cancer antigens are reviewed with a detailed description of the melanoma antigens discovered so far. The review also summarises clinical trials and individual clinical cases in which some of the old and current methods to vaccinate against or treat melanoma were used. These include vaccines made of autologous or allogenic melanoma tumour cells, melanoma peptides, recombinant bacterial or viral vectors, or dendritic cells.
Export Options
About this article
Cite this article as:
Saleh F., Renno W., Klepacek I., Ibrahim G., Asfar S., Dashti H., Romero P., Dashti A. and Behbehani A., Melanoma Immunotherapy: Past, Present, and Future, Current Pharmaceutical Design 2005; 11 (27) . https://dx.doi.org/10.2174/138161205774414529
DOI https://dx.doi.org/10.2174/138161205774414529 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Vascular Endothelial Cell Growth Factor (VEGF), An Emerging Target for Cancer Chemotherapy
Current Medicinal Chemistry - Anti-Cancer Agents A Study on Leukemic and Non-small Cell Lung Cancer Efficacy of Novel Isoxazoles Synthesized by Microwave Irradiation
Letters in Drug Design & Discovery Genetic Alterations in Poorly Differentiated and Undifferentiated Thyroid Carcinomas
Current Genomics Down-Regulation of Angiogenic Inhibitors: A Potential Pathogenic Mechanism for Diabetic Complications
Current Diabetes Reviews Strategies that Target Tight Junctions for Enhanced Drug Delivery
Current Pharmaceutical Design Phase II Drug Metabolism and Individualized Drug Therapy: A Focus on Functional Genetic Variation in UDP-Glucuronosyltransferases
Current Pharmacogenomics and Personalized Medicine Role of the Akt Pathway in Prostate Cancer
Current Cancer Drug Targets Recent Patents in Autophagy and Immune Response
Recent Patents on Inflammation & Allergy Drug Discovery Protein Kinase C ζ Drives Sphingomyelin Metabolism in the Nucleus During Cell Proliferation
Current Chemical Biology Protein-Protein Interactions and Cancer: Targeting the Central Dogma
Current Topics in Medicinal Chemistry Curcumin and Liver Cancer: A Review
Current Pharmaceutical Biotechnology Molecular Targets from VHL Studies into the Oxygen-Sensing Pathway
Current Cancer Drug Targets Multifunctional Hydroxyapatite-based Nanoparticles for Biomedicine: Recent Progress in Drug Delivery and Local Controlled Release
Current Mechanics and Advanced Materials Potential of DNMT and its Epigenetic Regulation for Lung Cancer Therapy
Current Genomics Anti-CTLA4 Monoclonal Antibody Ipilimumab in the Treatment of Metastatic Melanoma: Recent Findings
Recent Patents on Anti-Cancer Drug Discovery Role of NF-κB and NF-κB-regulated Gene Products in Chemoresistance and Radioresistance
Current Cancer Therapy Reviews Preclinical Evaluation of a Monoclonal Antibody (3C6) Specific for Prostate-Specific Membrane Antigen
Current Radiopharmaceuticals Correlation between Cancer Antigen 15.3 Value and Qualitative and Semiquantitative Parameters of Positron Emission Tomography/Computed Tomography in Breast Cancer Patients
Current Radiopharmaceuticals Mammalian DNA (Cytosine-5) Methyltransferase Mechanisms and RNA-Mediated Inhibition for Future Therapies
Epigenetic Diagnosis & Therapy (Discontinued) Anal Cancer: Focus on HIV-Positive Patients in the HAART Era
Current HIV Research